FDA issues Complete Response Letter for Eliquis (BMS/Pfizer) in Stroke Prevention - 26-Jun-2012

The FDA has issued a Complete Response Letter regarding the New Drug Application for Eliquis (apixaban) from BMS/Pfizer for the Prevention of Stroke and Systemic Embolism in patients with nonvalvular atrial fibrillation. The FDA requests additional information on data management and verification from the ARISTOTLE trial. BMS and Pfizer will work closely with the FDA on the appropriate next steps for the Eliquis application. The FDA has not requested that the companies complete any new studies.

Related News

Related Cardiology Information

Related Cardiology Drugs

Back to top

Latest News

10 May 2015
25 May 2013
25 May 2013